Ovitrelle (choriogonadotropin alfa)
- Region
- 🇪🇺 EU
- Active substance
- choriogonadotropin alfa
- Company
- Merck Europe B.V.
- Status
- Authorised
- Therapeutic area
- Anovulation; Reproductive Techniques, Assisted; Infertility, Female
- CHMP opinion
- Thu 19 Oct 2000
- EU approval
- Fri 02 Feb 2001
- Application
- EMEA/H/C/000320
- ATC
- G03GA08
- Official record
- www.ema.europa.eu
Indication
Ovitrelle is indicated in the treatment of: women undergoing superovulation prior to assisted reproductive techniques such as in vitro fertilisation (IVF): Ovitrelle is administered to trigger final follicular maturation and luteinisation after stimulation of follicular growth; anovulatory or oligo-ovulatory women: Ovitrelle is administered to trigger ovulation and luteinisation in anovulatory or oligo-ovulatory patients after stimulation of follicular growth.
Regulatory milestones
No milestones recorded in the last year.
Follow Ovitrelle
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.